Pricing Log in Create free account

Agenus Inc. (AGEN) vs Contineum Therapeutics, Inc. (CTNM)

Agenus Inc. and Contineum Therapeutics, Inc. are both Biotechnology companies. Agenus Inc. and Contineum Therapeutics, Inc. are of similar size ($301.7M and $297.2M). Contineum Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Agenus Inc. trades at 2.3×. Agenus Inc. has the higher net margin (69.2% vs 0.00%) and the higher return on invested capital (0.00% vs −1,334.4%). Across the 12 metrics below, Agenus Inc. leads on 8 and Contineum Therapeutics, Inc. on 4.

Valuation

Metric AGEN CTNM Biotechnology median
P/E 2.28 n/m 8.50
P/S 1.88 n/m 9.71
P/B n/m 1.10 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 6.95 n/m 0.64
EV/Sales 2.14 n/m 9.21
Earnings yield 43.81% (24.64%) (33.15%)
Free cash flow yield (39.31%) (20.33%) (25.50%)

Profitability

Metric AGEN CTNM Biotechnology median
Gross margin 99.52% — 65.16%
Operating margin 27.28% 0.00% 0.00%
Net margin 69.18% 0.00% 0.00%
Free cash flow margin (73.97%) 0.00% 0.00%
Return on equity (33.86%) (28.01%) (56.36%)
Return on assets 51.30% (26.57%) (48.04%)
Return on invested capital 0.00% (1,334.41%) 0.00%

Growth

Metric AGEN CTNM Biotechnology median
Revenue growth (TTM) 30.47% — 6.02%
EPS growth (last fiscal year) 100.00% 0.46% 30.26%
Revenue growth, 5-year CAGR 5.31% — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AGEN CTNM Biotechnology median
Debt to equity (0.15) 0.00 0.00
Current ratio 0.34 37.17 4.72
Net debt to EBITDA (4.10) 3.88 0.96

Dividend

Metric AGEN CTNM Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AGEN CTNM Biotechnology median
Market cap 301.68m 297.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack